- Home
- PHVS vs MLAB Comparison
PHVS vs MLAB Comparison
Compare PHVS & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- MLAB
- Stock Information
- Founded
- PHVS 2015
- MLAB 1982
- Country
- PHVS Netherlands
- MLAB United States
- Employees
- PHVS N/A
- MLAB N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- MLAB Industrial Machinery/Components
- Sector
- PHVS Health Care
- MLAB Industrials
- Exchange
- PHVS Nasdaq
- MLAB Nasdaq
- Market Cap
- PHVS 862.3M
- MLAB 757.3M
- IPO Year
- PHVS 2021
- MLAB N/A
- Fundamental
- Price
- PHVS $16.91
- MLAB $122.33
- Analyst Decision
- PHVS Strong Buy
- MLAB Hold
- Analyst Count
- PHVS 5
- MLAB 2
- Target Price
- PHVS $41.60
- MLAB $140.00
- AVG Volume (30 Days)
- PHVS 50.2K
- MLAB 33.2K
- Earning Date
- PHVS 05-07-2025
- MLAB 02-04-2025
- Dividend Yield
- PHVS N/A
- MLAB 0.52%
- EPS Growth
- PHVS N/A
- MLAB N/A
- EPS
- PHVS N/A
- MLAB N/A
- Revenue
- PHVS N/A
- MLAB $237,747,000.00
- Revenue This Year
- PHVS N/A
- MLAB $13.48
- Revenue Next Year
- PHVS N/A
- MLAB $4.74
- P/E Ratio
- PHVS N/A
- MLAB N/A
- Revenue Growth
- PHVS N/A
- MLAB 11.68
- 52 Week Low
- PHVS $14.14
- MLAB $83.68
- 52 Week High
- PHVS $26.57
- MLAB $155.12
- Technical
- Relative Strength Index (RSI)
- PHVS 55.23
- MLAB 32.81
- Support Level
- PHVS $14.49
- MLAB $134.91
- Resistance Level
- PHVS $17.00
- MLAB $142.19
- Average True Range (ATR)
- PHVS 1.32
- MLAB 5.93
- MACD
- PHVS 0.18
- MLAB -2.33
- Stochastic Oscillator
- PHVS 71.95
- MLAB 10.27
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.